Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo

Key Points:

• Intellia Therapeutics has initiated a rolling submission of a biologics license application (BLA) to the FDA for lonvo-z, an in vivo CRISPR gene editing therapy aimed at treating hereditary angioedema (HAE), with completion expected in the second half of 2026.
• Positive topline results from the Phase 3 HAELO trial showed that a single dose of lonvo-z significantly reduced HAE attacks and the need for ongoing therapy over six months, meeting all primary and key secondary endpoints.
• Lonvo-z, designed as a one-time outpatient treatment to inactivate the KLKB1 gene and lower kallikrein and bradykinin levels, has received multiple regulatory designations including Orphan Drug and RMAT from the FDA, and is anticipated to launch commercially in the first half of 2027 if approved.
• The FDA's RMAT designation and participation in the CMC Development and Readiness Pilot are expected to expedite the review process, potentially allowing for priority review and earlier patient access.
• Hereditary angioedema is a rare genetic disorder causing severe and unpredictable swelling attacks, currently managed by lifelong therapies; lonvo-z aims to offer a durable, potentially curative alternative with a single treatment.